Novo Nordisk (NVO) said Wednesday that two new Danish studies didn't show a causal relationship between Ozempic and a rare eye disease called nonarteritic anterior ischemic optic neuropathy or Naion.
"Naion is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and Wegovy) as per the approved labels," Novo Nordisk said in response to MT Newswires' request for comment on reports that the European Medicines Agency would evaluate the information in the studies.
Novo Nordisk said its opinion on semaglutide's benefit-risk profile remains the same after an evaluation of the studies from the University of Southern Denmark and the company's internal safety assessment.
"While both studies showed a roughly doubling of relative risk, the absolute risk and absolute number of people affected is very low," the company said. "This aligns with the very low annual incidence of this rare disorder."
Price: 107.91, Change: -0.10, Percent Change: -0.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。